Rein Therapeutics Inc (RNTX) Stock Price, Quote & News

Company Profile

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The com...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 802 1989

Website: www.reintx.com

Address:

12407 N. Mopac Expy., Suite 250 #390, Austin, United States

MomentumWins Jan. 20 at 1:54 PM

$SPY $QQQ looks like this will be green $RNTX

0 · Reply

DARKP00L Jan. 20 at 1:13 PM

$RNTX 08:08 on Jan. 20 2026 Rein Therapeutics Gets European Medicines Agency's Orphan Drug Designation For LTI-03 #tradeideas

0 · Reply

jamal1749 Jan. 20 at 1:09 PM

$RNTX trash

0 · Reply

jamal1749 Jan. 20 at 1:03 PM

$RNTX how did it go down on this news.

0 · Reply

premarketmaker Jan. 20 at 1:03 PM

$RNTX first resistance on ask - $3.05

0 · Reply

premarketmaker Jan. 20 at 1:02 PM

$RNTX very low amount of shares on the ask

0 · Reply

premarketmaker Jan. 20 at 1:01 PM

$RNTX orphan drug -pulmonary fibrosis lower float

0 · Reply

BillionerOfKing Jan. 19 at 10:14 AM

$RNTX Current Stock Price: $1.22

0 · Reply

MomentumWins Jan. 2 at 3:00 PM

$RNTX bull market is back. we should see 2’s again

0 · Reply

SuperGreenToday Dec. 30 at 2:46 PM

$RNTX

1 · Reply

Why Is Rein Therapeutics Stock Trading Higher On Monday?

Oct 9, 2025, 7:30 AM EDT - 3 months ago

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Sep 17, 2025, 7:30 AM EDT - 4 months ago

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

Aug 19, 2025, 8:00 AM EDT - 5 months ago

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Aug 14, 2025, 5:00 PM EDT - 5 months ago

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

Jun 24, 2025, 10:11 AM EDT - 7 months ago

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:18 PM EDT - 8 months ago

US FDA puts on hold Rein Therapeutics' lung disease drug trial

May 27, 2025, 7:00 AM EDT - 8 months ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

IQV

May 19, 2025, 4:51 PM EDT - 8 months ago

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 15, 2025, 4:09 PM EDT - 9 months ago

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 7:00 AM EDT - 9 months ago

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025, 7:00 AM EDT - 9 months ago

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Apr 30, 2025, 4:05 PM EDT - 9 months ago

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 28, 2025, 7:00 AM EDT - 9 months ago

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Apr 23, 2025, 7:00 AM EDT - 9 months ago

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Apr 15, 2025, 7:00 AM EDT - 10 months ago

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Apr 7, 2025, 4:17 PM EDT - 10 months ago

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

MomentumWins Jan. 20 at 1:54 PM

$SPY $QQQ looks like this will be green $RNTX

0 · Reply

DARKP00L Jan. 20 at 1:13 PM

$RNTX 08:08 on Jan. 20 2026 Rein Therapeutics Gets European Medicines Agency's Orphan Drug Designation For LTI-03 #tradeideas

0 · Reply

jamal1749 Jan. 20 at 1:09 PM

$RNTX trash

0 · Reply

jamal1749 Jan. 20 at 1:03 PM

$RNTX how did it go down on this news.

0 · Reply

premarketmaker Jan. 20 at 1:03 PM

$RNTX first resistance on ask - $3.05

0 · Reply

premarketmaker Jan. 20 at 1:02 PM

$RNTX very low amount of shares on the ask

0 · Reply

premarketmaker Jan. 20 at 1:01 PM

$RNTX orphan drug -pulmonary fibrosis lower float

0 · Reply

BillionerOfKing Jan. 19 at 10:14 AM

$RNTX Current Stock Price: $1.22

0 · Reply

MomentumWins Jan. 2 at 3:00 PM

$RNTX bull market is back. we should see 2’s again

0 · Reply

SuperGreenToday Dec. 30 at 2:46 PM

$RNTX

1 · Reply

KnowledgeKing Dec. 25 at 9:56 AM

$RNTX Upside depends on translating ambition into measurable cadence, while management calibrates resource allocation to real demand signals. The upside case requires evidence, not projection.

0 · Reply

Lockedin2024 Dec. 16 at 9:24 PM

$RNTX time for some volume.. tomorrow maybe :)

0 · Reply

BrianWindsor Nov. 24 at 2:12 PM

Trying to make the science behind IPF more accessible. Here’s a quick breakdown of pulmonary fibrosis and why it matters for patients and investors following this field. 🎥 https://youtu.be/n6J_Cacf25w $RNTX

0 · Reply

Jobsworth Nov. 23 at 5:05 PM

$RNTX

0 · Reply

MomentumWins Nov. 19 at 4:24 AM

$RNTX Healthcare sector rotation in full force. This should catch fire for sure here

0 · Reply

DARKP00L Nov. 19 at 12:03 AM

$RNTX this stock is seeing a surge in interest. Market volatility might ensue!

0 · Reply

BrianWindsor Nov. 18 at 7:21 PM

Our Chief Scientist, Cory Hogaboam, dives into the science behind LTI-03 and why we believe it represents a fundamentally different approach to treating IPF. He breaks down the mechanism, the multi-pathway impact, and why protecting alveolar progenitor cells could matter for long-term lung repair. We think it could be a real game changer for IPF. 🎥 Watch here: https://youtu.be/rPxJddSzZPQlink $RNTX

0 · Reply

MomentumWins Nov. 14 at 2:39 PM

$RNTX this is too small to trade along indexes. it was 1.61 before the fda removed the hold. you expect it to be higher. They have lots of cash to survive

0 · Reply

d_risk Nov. 14 at 1:11 PM

$RNTX - Rein Therapeutics, Inc. - 10Q - Updated Risk Factors RNTX warns it needs significant new funding to continue operations and, given ongoing losses and limited cash, there’s substantial doubt about its ability to remain a going concern. #Biotechnology #CashFlow #GoingConcern #FundingChallenges #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/RNTX/10-Q/2025-11-14

0 · Reply

daintylava Nov. 10 at 7:38 PM

$RNTX going up now

0 · Reply

Market Cap	31.81M
Revenue (ttm)	0.00
Net Income (ttm)	-62.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	185,400
Avg Vol	226,056
Day's Range	N/A - N/A
Shares Out	26.29M
Stochastic %K	81%
Beta	1.31
Analysts	Sell
Price Target	$8.00